C-Reactive protein as a prognostic marker after lacunar stroke levels of inflammatory markers in the treatment of stroke study

Stroke

Volumn 45, Issue 3, 2014, Pages 707-716

  Elkind, Mitchell S V ^a,b,c   Luna, Jorge M ^a,b   McClure, Leslie A ^d   Zhang, Yu ^d   Coffey, Christopher S ^e   Roldan, Ana ^f   Del Brutto, Oscar H ^g   Pretell, Edwin Javier ^h   Creed Pettigrew, L ⁱ   Meyer, Brett C ^j   Tapia, Jorge ^k   White, Carole ^l   Benavente, Oscar R ^m  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Medicine   (United States)

^c Vagelos College of Physicians and Surgeons   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSIDAD ESPÍRITU SANTO   (Ecuador)

^h HOSPITAL NACIONAL ALBERTO SABOGAL SOLOGUREN   (Peru)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j UNIVERSITY OF SAN DIEGO   (United States)

^k PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^l Coordinating Center School of Nursing and Secondary Prevention of Small Subcortical Strokes ^*  (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

C reactive protein; Inflammation; Prognosis; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; AUTACOID; BIOLOGICAL MARKER; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ADULT; ARTICLE; BLOOD PRESSURE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FACTORIAL DESIGN; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NEPHELOMETRY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHLEBOTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; SECONDARY PREVENTION; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INFLAMMATION; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE; TREATMENT OUTCOME;

C-REACTIVE PROTEIN; INFLAMMATION; PROGNOSIS; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PHLEBOTOMY; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; SAMPLE SIZE; STROKE, LACUNAR; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84899134280     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.004562     Document Type: Article

References (50)

1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499-511.
2. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316-1329.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med. 2008;359:2195-2207.
5. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
6. Chamorro A, Sacco RL, Mohr JP, Foulkes MA, Kase CS, Tatemichi TK, et al. Clinical-computed tomographic correlations of lacunar infarction in the Stroke Data Bank. Stroke. 1991;22:175-181.
7. Wolfe CD, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: The South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002;72:211-216.
8. Ross GW, Petrovitch H, White LR, Masaki KH, Li CY, Curb JD, et al. Characterization of risk factors for vascular dementia: The Honolulu- Asia Aging Study. Neurology. 1999;53:337-343.
9. Tatemichi TK, Desmond DW, Paik M, Figueroa M, Gropen TI, Stem Y, et al. Clinical determinants of dementia related to stroke. Ann Neurol. 1993;33:568-575.
10. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction: The Oxfordshire Community Stroke Project. Stroke. 1987;18:545-551.
11. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al; Warfarin- Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
12. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: A population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31:1062-1068.
13. Salgado AV, Ferro JM, Gouveia-Oliveira A. Long- Term prognosis of first-ever lacunar stroke. Stroke. 1996;27:661-666.
14. Arboix A, Marti-Vilalta JL, Garcia JH. Clinical study of 227 patients with lacunar infarcts. Stroke. 1990;21:842-847.
15. Lammie AG, Brannan F. Nonhypertensive cerebral small-vessel disease. Stroke. 1997;28:2222-2229.
16. Mast H, Thompson JL, Lee SH, Mohr JP, Sacco RL. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke. 1995;26:30-33.
17. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
18. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, et al. Total homocysteine is associated with white matter hyperintensity volume: The Northern Manhattan Study. Stroke. 2005;36:1207-1211.
19. Young VG, Halliday GM, Kril JJ. Neuropathology correlates of white matter hyperintensities. Neurology. 2008;71:804-811.
20. Lammie GA, Brannan F, Slattery J, Warlow C. Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke. 1997;28:2222-2229.
21. Gan R, Sacco RL, Kargman DE, Roberts JK, Boden- Albala B, Gu Q. Testing the validity of the lacunar hypothesis: The Northern Manhattan Stroke Study experience. Neurology. 1997;48:1204-1211.
22. Revilla M, Obach V, Cervera A, DSvalos A, Castillo J, Chamorro A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett. 2002;324:29-32.
23. Rundek T, Elkind MS, Pittman JG, Boden- Albala B, Humphries SE, Sacco RL. Increased carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6 and hepatic lipase genes: The Northern Manhattan Prospective Cohort Study. Stroke. 2002;33:1420-1423.
24. Castellanos M, Castillo J, Garcfa MM, Leira R, Serena J, Chamorro A, et al. Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke. 2002;33:982-987.
25. Elkind MS, Tondella ML, Feikin DR, Fields BS, Homma S, Di Tullio MR. Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke. 2006;37:790-795.
26. Elkind MS, Cheng J, Rundek T, Boden- Albala B, Sacco RL. Leukocyte count predicts outcome after ischemic stroke: The Northern Manhattan Stroke Study. J Stroke Cerebrovasc Dis. 2004;13:220-227.
27. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825.
28. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al; SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet. 2013;382:507-515.
29. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al; SPS3 Investigators. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke. 2011;6:164-175.
30. Elkind MS, Luna JM, Coffey CS, McClure LA, Liu KM, Spitalnik S, et al. The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): Inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke. 2010;5:117-125.
31. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
32. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32:133-138.
33. McClure LA, Szychowski JM, Benavente O, Coffey CS. Sample size re-estimation in an on-going NIH-sponsored clinical trial: The secondary prevention of small subcortical strokes experience. Contemp Clin Trials. 2012;33:1088-1093.
34. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vase Biol. 2000;20:1052-1056.
35. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vase Biol. 2000;20:1047-1051.
36. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. Stroke. 2001;32:2575-2579.
37. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020.
38. Elkind MSV, Luna JM, Moon YP, Liu KM, Spitalnik S, Paik MC, et al. High-sensitivity C-reactive protein predicts mortality but not stroke in a multi-ethnic cohort: The Northern Manhattan Study. Neurology. 2009;73:1300-1307.
39. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta- Analysis. Lancet. 2010;375:132-140.
40. Arenillas JF, Alvarez-Sabfn J, Molina CA, Chacón P, Montaner J, Rovira A, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large- Artery occlusive disease. Stroke. 2003;34:2463-2468.
41. Elkind MS V, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein- Associated phospholipase A2, C-reactive protein, and outcome after ischemic stroke. Arch Int Med. 2006;166:2073-2080.
42. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-2147.
43. Elkind MS, Leon V, Moon YP, Paik MC, Sacco RL. High-sensitivity C-reactive protein and lipoprotein- Associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke. 2009;40: 3233-3237.
44. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121:143-150.
45. Cruz-Flores S, Rabinstein A, Biller J, Elkind MSV, Griffith P, Gorelick P, et al. Race-ethnic disparities in stroke care: The American Experience. A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on stroke. Stroke. 2011;42:2091-2116.
46. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams R, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. Stroke. 1999:29:447-453.
47. Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, et al. Medical complications after stroke: A multicenter study. Stroke. 2000;31:1223-1229.
48. Sacco RL, DeRosa JT, Haley EC, Levin B, Ordronneau P, Phillips SJ, et al. Glycine antagonist in neuroprotection for patients with acute stroke. GAIN Americas: A randomized controlled trial. J Am Med Assoc. 2001;285:1719-1728.
49. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke. 1996;27:415-420.
50. Grau AJ, Buggle F, Schnitzler P, Spiel M, Lichy C, Hacke W. Fever and infection early after ischemic stroke. J Neurol Sci. 1999; 171:115-120.